LB-P6
/ LISCure Biosci
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
September 06, 2022
A Study to Assess the Safety and Tolerability of LB-P6 and LB-P8 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=31 | Completed | Sponsor: LISCure Biosciences | Recruiting ➔ Completed
Trial completion • Hepatology • Immunology • Inflammatory Arthritis • Non-alcoholic Steatohepatitis • Rheumatoid Arthritis • Rheumatology
December 30, 2021
A Study to Assess the Safety and Tolerability of LB-P6 and LB-P8 in Healthy Participants
(clinicaltrials.gov)
- P1; N=30; Recruiting; Sponsor: LISCure Biosciences; Not yet recruiting ➔ Recruiting; Trial completion date: Jan 2022 ➔ Jun 2022; Trial primary completion date: Nov 2021 ➔ Apr 2022
Clinical • Enrollment open • Trial completion date • Trial primary completion date • Hepatology • Immunology • Inflammatory Arthritis • Non-alcoholic Steatohepatitis • Rheumatoid Arthritis • Rheumatology
1 to 2
Of
2
Go to page
1